BioSurfaces, a Massachusetts-based nanofiber materials firm, is joining forces with Morphocell Technologies to explore its proprietary Bio-Spun material for therapeutic applications.
Morphocell Technologies is a Canada-based company specialising in regenerative medicine. The company focuses on cell therapies and engineered tissues aimed at treating severe organ deficiencies and is dedicated to creating innovative solutions for critical patient needs.
The collaboration will harness the unique properties of Bio-Spun material to drive innovations in regenerative medicine.
Morphocell Technologies CEO Massimiliano Paganelli said: “At Morphocell, we are always looking for cutting-edge technologies that can help us improve patient outcomes.
“BioSurfaces has developed an exciting material, and we look forward to working together to explore its potential in advancing therapeutic approaches for patients in need.”
By combining BioSurfaces’ expertise in biomaterials with Morphocell’s proficiency in cell-based therapies, the companies intend to develop solutions addressing significant healthcare challenges.
The initial focus will be on early-stage research to evaluate Bio-Spun’s potential across various therapeutic applications, with the ultimate goal of advancing regenerative treatments globally.
BioSurfaces president and CEO Matthew Phaneuf said: “We are excited to collaborate with Morphocell, a company at the forefront of regenerative medicine.
“Our shared mission is to innovate and develop solutions that can ultimately improve lives. This partnership represents an important step in that direction.”
BioSurfaces specialises in developing advanced nanofiber materials to enhance product development and commercialisation across life sciences tools, medical devices, and consumer products. The company is said to collaborate with major life science organisations worldwide.
In November 2024, BioSurfaces received a grant of over $2m from the Bill & Melinda Gates Foundation. This funding will support the advancement of Bio-Spun Cell Chamber (BSCC), a device engineered for long-term delivery of biotherapeutic agents to treat chronic illnesses.
The BSCC encapsulates genetically engineered cells producing therapeutic proteins.
Through comprehensive pre-clinical research funded by the grant, BioSurfaces aims to demonstrate the BSCC’s capability in achieving key goals for implantable cell therapy delivery, which include nutrient provision from the body, immune system protection, and therapeutic agent delivery into the body.
